Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania

Journal of Medical Virology

Volumn 86, Issue 3, 2014, Pages 404-410

  Fall Malick, F Zahra ^a   Tchiakpé, Edmond ^b   Ould Soufiane, Sid'Ahmed ^c,d   Diop Ndiaye, Halimatou ^b   Mouhamedoune Baye, Abderrahmane ^c   Ould Horma Babana, Abdallah ^e   Kane, Coumba Touré ^b   Lo, Baidy ^d   Mboup, Souleymane ^b  

^a Public Health National Institute (INRSP)   (Mauritania)

^b University Hospital Aristide Le Dantec   (Senegal)

^c National Hospital Center of Nouakchott   (Mauritania)

^d Faculty of Medicine   (Mauritania)

^e Military Hospital of Nouakchott   (Mauritania)

Author keywords

Genetic diversity; HIV 1; Mauritania; Therapeutic failure

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CROSS-SECTIONAL STUDY; DRUG RESISTANCE MUTATION; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; MAURITANIA; MIDDLE AGED; PHYLOGENY; TREATMENT DURATION; VIRUS LOAD; YOUNG ADULT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

GENETIC DIVERSITY; HIV-1; MAURITANIA; THERAPEUTIC FAILURE;

ADULT; ANTI-HIV AGENTS; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MAURITANIA; MIDDLE AGED; MUTATION, MISSENSE; PHYLOGENY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TIME FACTORS; VIRAL LOAD; YOUNG ADULT;

EID: 84891960215     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23860     Document Type: Article

References (32)

1. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. 2010. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: A systematic review. Lancet Infect Dis 10:155-166.
2. Chaplin B, Eisen G, Idoko J, Onwujekwe D, Idigbe E, Adewole I, Gashau W, Meloni S, Sarr AD, Sankale JL, Ekong E, Murphy RL, Kanki P. 2011. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy. AIDS Res Hum Retroviruses 27:71-80.
3. Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M. 2011. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc 14:30.
4. El Annaz H, Recordon-Pinson P, Tagajdid R, Doblali T, Belefquih B, Oumakhir S, Sedrati O, Mrani S, Fleury H. 2012. Drug resistance mutations in HIV type 1 isolates from patients failing antiretroviral therapy in Morocco. AIDS Res Hum Retroviruses 28:944-948.
5. El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L. 2010. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: A cross-sectional study in Soweto, South Africa. AIDS 24:1679-1687.
6. Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. 2013. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis 207:S49-S56.
7. Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, Matee MI, Gundersen SG, Bruun JN. 2009. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 9:108.
8. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 19:156-164.
9. Jordan MR. 2011. Assessments of HIV drug resistance mutations in resource-limited settings. Clin Infect Dis 52:1058-1060.
10. Kebe M, Fall-Malick FZ, Elghady OI, Ebnou OH, Bara OA, Lam M, Beibacar MO, Diallo MY, Keita M, Sy I, Bellaty AJ, Ly C, LO BB. 2011. Séroprévalence VIH chez les consultants IST à Nouakchott et à Nouadhibou (Mauritanie). Bull Soc Pathol Exot 104:374-377.
11. Kebe K, Thiam M, Diagne Gueye NR, Diop H, Dia A, Signate Sy H, Charpentier C, Belec L, Mboup S, Toure Kane C. 2013. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. AIDS Res Hum Retroviruses 29:242-249.
12. Kouanfack C, Montavon C, Laurent C, Aghokeng A, Kenfack A, Bourgeois A, Koulla-Shiro S, Mpoudi-Ngole E, Peeters M, Delaporte E. 2009. Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 48:1318-1322.
13. Maiga AI, Fofana DB, Cisse M, Diallo F, Maiga MY, Traore HA, Maiga IA, Sylla A, Fofana D, Taiwo B, Murphy R, Katlama C, Tounkara A, Calvez V, Marcelin AG. 2012. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. J Antimicrob Chemother 67:2943-2948.
14. Maiga AI, Fofana DB, Maiga AC, Diallo F, Ait-Arkoub Z, Daou F, Cisse M, Sarro YD, Oumar AA, Sylla A, Katlama C, Taiwo B, Murphy R, Tounkara A, Marcelin AG, Calvez V. 2013. Transmitted antiretroviral drug resistance in newly HIV-infected and untreated patients in Segou and Bamako, Mali. AIDS Res Hum Retroviruses 29:182-186.
15. Mamadou S, Hanki Y, Ali Maazou AR, Aoula B, Diallo S. 2011. Genetic diversity and drug resistance mutations in HIV-1 from untreated patients in Niamey, Niger. ISRN Microbiol 2011:797463.
16. Messou E, Chaix ML, Gabillard D, Yapo V, Toni TD, Minga A, Kouakou MG, Ouattara E, Rouzioux C, Danel C, Eholie SP, Anglaret X. 2013. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: The VOLTART cohort study in Cote d'Ivoire, West Africa. J Acquir Immune Defic Syndr 64:211-219.
17. Ministère de la Santé-Mauritanie. 2011. Processus d'élaboration du plan de développement Sanitaire (2012-2020). Rapport d'analyse de situation du secteur de la santé. http://www.internationalhealthpartnership.net/fileadmin/uploads/ihp/Documents/Country_Pages/Mauritania/Analyse%20de%20situation%20secteur%20de%20sant%202011%20VF.pdf [Acceded August 15, 2013].
18. Mohamad S, Deris ZZ, Yusoff NK, Ariffin TA, Shueb RH. 2012. Assessing subtypes and drug resistance mutations among HIV-1 infected children who failed antiretroviral therapy in Kelantan, Malaysia. Braz J Infect Dis 16:284-288.
19. Mumtaz G, Hilmi N, Akala FA, Semini I, Riedner G, Wilson D, Abu-Raddad LJ. 2011. HIV-1 molecular epidemiology evidence and transmission patterns in the Middle East and North Africa. Sex Transm Infect 87:101-106.
20. Pere H, Charpentier C, Mbelesso P, Dandy M, Matta M, Moussa S, De Dieu Longo J, Gresenguet G, Abraham B, Belec L. 2012. Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic. AIDS Res Hum Retroviruses 28:315-323.
21. Petersen ML, van der Laan MJ, Napravnik S, Eron JJ, Moore RD, Deeks SG. 2008. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 22:2097-2106.
22. Revell AD, Wang D, Harrigan R, Hamers RL, Wensing AM, Dewolf F, Nelson M, Geretti AM, Larder BA. 2010. Modelling response to HIV therapy without a genotype: An argument for viral load monitoring in resource-limited settings. J Antimicrob Chemother 65:605-607.
23. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF. 2011. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr 58:23-31.
24. Soares EA, Makamche MF, Siqueira JD, Lumngwena E, Mbuagbaw J, Kaptue L, Asonganyi T, Seuanez HN, Soares MA, Alemnji G. 2010. Molecular diversity and polymerase gene genotypes of HIV-1 among treatment-naive Cameroonian subjects with advanced disease. J Clin Virol 48:173-179.
25. Sturmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S. 2007. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antivir Ther 12:25-30.
26. Thiam M, Diop-Ndiaye H, Diouf AD, Vidal N, Ndiaye O, Ndiaye I, Ngom-Gueye NF, Diallo S, Diongue OD, Camara M, Seck A, Mboup S, Toure-Kane C. 2013. HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. J Clin Microbiol 51:578-584.
27. Tongo M, Martin DP, Zembe L, Mpoudi-Ngole E, Williamson C, Burgers WA. 2013. Characterization of HIV-1 gag and nef in Cameroon: Further evidence of extreme diversity at the origin of the HIV-1 group M epidemic. Virol J 10:29.
28. UNAIDS. 2011. Estimations VIH ET SIDA. http://www.unaids.org/fr/regionscountries/countries/mauritania/ [Accessed August 14, 2013].
29. UNAIDS. 2012a. Rapport d'activités sur la réponse sur le VIH/SIDA en Mauritanie. http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_MR_Narrative_Report%5B1%5D.pdf [Accessed August 14, 2013].
30. UNAIDS. 2012b. UNAIDS report on the global AIDS epidemic 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf [Accessed August 14, 2013].
31. World Health Organization. 2010. Antiretroviral therapy for HIV infection in adults and adolescents-recommendations for a public health approach: 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf [Accessed August 28, 2013].
32. World Health Organization. 2013. Consolidated guidelines on the use of antiretroviral drugs for treating, preventing HIV infection recommendations for a public health approach: 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf [Accessed, October12, 2013].